DOCKET NO.: M0765.70047US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Eng H. Lo et al.
Serial No.:	10/540,344
Confirmation No.:	6440
Filed:	May 15, 2006
For:	METHODS AND COMPOSITIONS FOR PROTECTION AGAINST THROMBOLYSIS-ASSOCIATED REPERFUSION INJURY
Examiner:	Not Yet Assigned
Art Unit:	1646

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 31st day of August, 2006.

Melissa L.B. Lyons

MAIL STOP Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith are the following documents:

- Information Disclosure Statement
- PTO Form 1449 with cited references
- Return Receipt Postcard

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 646-8000, Boston, Massachusetts.

A check is not enclosed. If a fee is required, the Commissioner is hereby authorized to charge Deposit Account No. 23/2825. A duplicate of this sheet is enclosed.

Respectfully submitted,

By:

MaryDilys S. Anderson, Ph.D.
Reg. No. 52,560
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: M0765.70047US01
Date: August 31, 2006
xNDDx

7

DOCKET NO.: M0765.70047US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Eng H. Lo et al.
Serial No.:	10/540,344
Confirmation No.:	6440
Filed:	May 15, 2006
For:	METHODS AND COMPOSITIONS FOR PROTECTION AGAINST THROMBOLYSIS-ASSOCIATED REPERFUSION INJURY
Examiner:	Not Yet Assigned
Art Unit:	1646

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to MAIL STOP Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the 31st day of August, 2006.

Melissa L.B. Lyons

MAIL STOP Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, the Applicant requests consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing of a first Office action on the merits in the above-identified case.

No fee or certification is required.

PART II: Information Cited

The Applicant hereby makes of record in the above-identified application the information listed on the attached form PTO-1449 (modified PTO/SB/08). The order of presentation of the references should not be construed as an indication of the importance of the references.

The Applicant hereby makes the following additional information of record in the above-identified application.

1. The above-identified U.S. application claims priority to application Serial No. PCT/US2003/040953. If the Examiner has not had the benefit of review of the file history of PCT/US2003/040953, then he/she is asked to contact the undersigned, who will provide a copy of same.

The Applicant would like to bring to the Examiner's attention the enclosed search report from a corresponding International or Foreign National Application: PCT/US2003/040953.

PART III: Remarks

Documents cited anywhere in the Information Disclosure Statement are enclosed unless otherwise indicated. It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;

2. The enclosed form PTO-1449 (modified PTO/SB/08) be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;

3. The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, the Applicant makes no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully submitted,

By: 

MaryDilys S. Anderson, Ph.D.
Reg. No. 52,560
Wolf, Greenfield & Sacks, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2206
Telephone: (617) 646-8000

Docket No.: M0765.70047US01
Date: August 31, 2006
xNDDx

FORM PTO-1449/A and B (modified PTO/SB/08)	APPLICATION NO.: 10/540,344	ATTY. DOCKET NO.: M0765.70047US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	FILING DATE: May 15, 2006	CONFIRMATION NO.: 6440
	APPLICANT: Eng H. Lo et al.	
Sheet 1 of 3	GROUP ART UNIT: 1646	EXAMINER: Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner's Initials #	Cite No.	U.S. Patent Document Number	U.S. Patent Document Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication or Issue of Cited Document MM-DD-YYYY
	A1	4,766,075		David V. Goeddel et al.	08-23-1988
	A2	2005-0019329	A1	Lawrence et al.	05-20-2003

FOREIGN PATENT DOCUMENTS

Examiner's Initials #	Cite No.	Foreign Patent Document Office/ Country	Foreign Patent Document Number	Foreign Patent Document Kind Code	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
	B1	WO	93/24635				
	B2	EP	339,505	A			

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
	C1	AHERN, T.J. et al., Site-directed mutagenesis in human tissue-plasminogen activator. Distinguishing sites in the amino-terminal region required for full fibrinolytic activity and rapid clearance from the circulation. J Biol Chem. 265(10): 5540-5545, 1990.	
	C2	ALBERS et al. Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 483S-512S, 2004.	
	C3	AOKI, T., et al., Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 33:2711-2717, 2002.	
	C4	ASAHI, M., et al., Role for matrix metalloproteinase 9 after focal cerebral ischemia: effects of gene knockout and enzyme inhibition with BB-94. J Cereb Blood Flow Metab 20:1681-1690, 2000.	
	C5	ASAHI, M., et al., Effects of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 21:7724-7732, 2001.	
	C6	BESCHORNER, R., et al., Lesion-associated accumulation of uPAR/CD87- expressing infiltrating granulocytes, activated microglial cells/macrophages and upregulation by endothelial cells following TBI and FCI in humans. Neuropath. Appl. Neurobiol. 26:522-527, 2000.	
	C7	HACKE, W. et al., Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS) JAMA 274:1017-1025, 1995.	
	C8	HACKE W, et. al., Thrombolysis in acute ischemic stroke: controlled trials and clinical experience. Neurology 53 (Suppl 4):s3-s15, 1999.	

	C9	HAHN-DANTONA, et al., The low density lipoprotein receptor-related protein modulates levels of matrix metalloproteinase 9 (MMP-9) by mediating its cellular catabolism. J. Biol. Chem. 276(18):15498-15503, 2001.	
	C10	HERZ, J. The LDL receptor gene family: (un)expected signal transducers in the brain. Neuron. 29(3): 571-581, 2001.	
	C11	HOTCHKISS, A. et al., The activity of a single chain rt-PA mutant in a primates and rabbits. Throm. Haemostas 55: 491, 1987.	
	C12	LAPCHAK et al., Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke, 31:3034-3040, 2000.	
	C13	JOHANNESSEN, M. et al., Fibrin affinity and clearance of t-PA deletion and substitution analogues. Thromb Haemost. 63(1): 54-59, 1990.	
	C14	LARRUE V, et. al., Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 28:957-960, 1999.	
	C15	LO et al., Extracellular proteolysis in brain injury and inflammation: role for plasminogen activators and matrix metalloproteinases. J. Neurosci. Res. 69:1-9, 2002.	
	C16	MARTIN, U. et al., Thrombolytic potency of an E. Coli-produced novel variant of rt-PA in dogs. Fibrinolysis 4: 9, 1990.	
	C17	MONTANER et al., Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 32:1759-1766, 2001.	
	C18	MONTANER, et. al, Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke, 32:2762-2767, 2001.	
	C19	MORI T., et al., Downregulation of matrix metalloproteinase-9 and attenuation of edema via inhibition of ERK mitogen activated protein kinase in traumatic brain injury. J. Neurotrauma 19(11):1411-1419, 2002.	
	C20	NINDS rt-PA Stroke Study Group, Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. New Engl J Med 333:1581-1587, 1995.	
	C21	NINDS rt-PA Stroke Study Group, Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke 28:2109-2118, 1997.	
	C22	SOBEL, B.E. et al., Augmented and sustained plasma concentrations after intramuscular injections of molecular variants and deglycosylated forms of tissue-type plasminogen activators. Circulation. 81(4): 1362-1373, 1990.	
	C23	SUMII, T., and E.H. Lo, Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 33:831-836, 2002.	
	C24	SUZUKI, S. et al., Intracoronary infusion of E6010 has more potent thrombolytic activity than tissue plasminogen activator (t-PA) in dogs: a higher plasma level of E6010 than t-PA causes potent thrombolytic activity. J Cardiovasc Pharmacol. 1993 22(6): 834-840, 1993.	
	C25	WANG X, et al., Tissue type plasminogen activator amplifies hemoglobin-induced neurotoxicity in rat neuronal cultures. Neurosci Lett 274:79-82, 1999.	
	C26	WILLNOW, T.E. et al., Lipoprotein receptors: new roles for ancient proteins. Nat Cell Biol. 1(6): E157-E162, 1999.	

	C27	ZHANG et al. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 106(6): 740-745, 2002.	

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. __ , filed __ , and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]